Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio b